National Anti-vivisection Society

 

National Antivisection Society

Objection letter to AstraZeneca planning application 14/1633/REM

Posted: 12 November 2014. Updated: 12 November 2014




Dear Sir / Madam

I am writing to make an objection to planning application 14/1633/REM for the global headquarters of AstraZeneca at the Cambridge Bio Medical Campus.

The reasons for my objection to this application are based on the following:

There is little information included in the application about the proposed use of animals
Despite having submitted a planning application which runs to hundreds of pages and contains a great level of detail about many aspects of the project, there is very little mention of animal use or facilities. There is a general note of their use in the Planning statement (pg 37), in which it is claimed that "AstraZeneca is committed to the responsible use of animals and their welfare is a top priority at all times...They also work to refine existing methods. The 3Rs (replace, reduce, refine) are at the centre of AstraZeneca´s commitment to good science and the responsible use of animals". Given the level of animal use by AstraZeneca, it is concerning that no detail has been given about how they would be housed and how welfare would be maximised in this new building.

The UK has an obligation to work towards ending animal experiments
The UK has an obligation under EU Directive 2010/63/EU, which has now been implemented into UK law, to work towards the "full replacement of procedures on live animals for scientific and educational purposes as soon as it is scientifically possible to do so". According to AstraZeneca´s own figures, in 2013 they used or commissioned the use of 280,606 animals. While this is a reduction on the total of 328,000 used in 2012, it still represents more than 5% of the total number of animals used in Great Britain. AstraZeneca have previously said that they will allow other factors to determine the number of animals they use and do not appear to commit to continuing the declining trend recently seen in their use of animals.

The use of animals in experiments is set to decline in the future
The UK has a duty under EU law, through Directive 2010/63/EU, to "contribute to the development and validation of alternative approaches which could provide the same or higher levels of information as those obtained in procedures using animals." The market for in vitro/in silico products and services, which included computer modelling and advanced tissue and cells cultures, is now about the same size as the contract research testing industry, and is projected to double by 2017. It would therefore be pertinent for AstraZeneca to acknowledge this shift away from animal use and highlight how they will facilitate the development of alternative methods.

AstraZeneca operating profit for the third quarter of 2014 was $1,770 million, with an operating profit of $5,753 million for the first nine months of 2014. With such levels of profits to invest in advanced and cutting edge technologies, few non-animal tests should be out of reach to AstraZeneca. It would be an economic advantage to Cambridge as sophisticated new technologies which do not involve outdated animal testing are developed and this new knowledge built upon.

If approval should be granted for this application, I hope that AstraZeneca will commit to the continued reduction of its use of animals, and ultimately the replacement of all research on animals, the ultimate goal of the EU Directive, which is now UK law. In the meantime I hope that they will outline in some detail the steps which will be taken to ensure that the facilities comply fully with UK regulations.

Yours faithfully

© National Anti-Vivisection Society

Cookie preferences